Reported Sunday, Gilead's Kite Presents Real-World Data At ASCO 2025 Supporting Outpatient Use Of Yescarta For R/R Large B-Cell Lymphoma With Comparable Safety And Efficacy

-3.70%

Gilead Sciences, Inc.

GILD

0.00

Reported Sunday, Gilead's Kite Presents Real-World Data At ASCO 2025 Supporting Outpatient Use Of Yescarta For R/R Large B-Cell Lymphoma With Comparable Safety And Efficacy

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

In Oct, Gilead Sciences Reached Settlement With A Tax Authority Related To A Prior Year Legal Entity Restructuring; Sees $450M Of Income Tax Benefit And A Corresponding $530M Reduction In Unrecognized Tax Benefits In Quarter Ending Dec 31

BRIEF-Metsera Says Pfizer to Buy Metsera For Up To $86.25 Per Share

Why Vericel (VCEL) Is Up 11.1% After Record Q3 Results and Reaffirmed 2025 Guidance

Dynavax Technologies Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Ultragenyx Pharmaceutical (RARE): Exploring Valuation Gaps and Analyst Targets

Beam Therapeutics (BEAM): Evaluating Valuation as Clinical Progress Drives Renewed Investor Focus

Assessing Vertex Pharmaceuticals (VRTX) Valuation as Shares Pause After Strong Multi-Year Gains

Revolution Medicines (RVMD): Valuation Perspective as FDA Designations and Pipeline Progress Spark New Optimism